Conor McNamara
Stock Analyst at RBC Capital
(0.68)
# 3,725
Out of 4,754 analysts
109
Total ratings
16.05%
Success rate
-17.27%
Average return
Main Sectors:
Stocks Rated by Conor McNamara
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QDEL QuidelOrtho | Maintains: Outperform | $64 → $61 | $39.05 | +56.21% | 11 | Feb 13, 2025 | |
| AVTR Avantor | Maintains: Outperform | $33 → $31 | $15.87 | +95.34% | 6 | Feb 10, 2025 | |
| ILMN Illumina | Maintains: Outperform | $250 → $247 | $84.20 | +193.35% | 13 | Feb 7, 2025 | |
| HOLX Hologic | Maintains: Sector Perform | $88 → $85 | $63.27 | +34.34% | 9 | Feb 6, 2025 | |
| TECH Bio-Techne | Maintains: Sector Perform | $79 → $80 | $61.19 | +30.74% | 8 | Feb 6, 2025 | |
| DHR Danaher | Reiterates: Outperform | $299 → $277 | $205.69 | +34.67% | 8 | Jan 30, 2025 | |
| BIO Bio-Rad Laboratories | Reiterates: Outperform | $481 | $256.45 | +87.56% | 10 | Jan 14, 2025 | |
| BIO.B Bio-Rad Laboratories | Reiterates: Outperform | $481 | $265.82 | +80.95% | 10 | Jan 14, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $17 → $13 | $3.02 | +330.46% | 6 | Nov 8, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $767 → $718 | $523.64 | +37.12% | 13 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $205 | $155.38 | +31.93% | 9 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $3.42 | +104.68% | 2 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $3.57 | +96.08% | 4 | Aug 7, 2024 |
QuidelOrtho
Feb 13, 2025
Maintains: Outperform
Price Target: $64 → $61
Current: $39.05
Upside: +56.21%
Avantor
Feb 10, 2025
Maintains: Outperform
Price Target: $33 → $31
Current: $15.87
Upside: +95.34%
Illumina
Feb 7, 2025
Maintains: Outperform
Price Target: $250 → $247
Current: $84.20
Upside: +193.35%
Hologic
Feb 6, 2025
Maintains: Sector Perform
Price Target: $88 → $85
Current: $63.27
Upside: +34.34%
Bio-Techne
Feb 6, 2025
Maintains: Sector Perform
Price Target: $79 → $80
Current: $61.19
Upside: +30.74%
Danaher
Jan 30, 2025
Reiterates: Outperform
Price Target: $299 → $277
Current: $205.69
Upside: +34.67%
Bio-Rad Laboratories
Jan 14, 2025
Reiterates: Outperform
Price Target: $481
Current: $256.45
Upside: +87.56%
Bio-Rad Laboratories
Jan 14, 2025
Reiterates: Outperform
Price Target: $481
Current: $265.82
Upside: +80.95%
Maravai LifeSciences Holdings
Nov 8, 2024
Maintains: Outperform
Price Target: $17 → $13
Current: $3.02
Upside: +330.46%
Thermo Fisher Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $767 → $718
Current: $523.64
Upside: +37.12%
Sep 26, 2024
Reiterates: Outperform
Price Target: $205
Current: $155.38
Upside: +31.93%
Aug 16, 2024
Reiterates: Outperform
Price Target: $7
Current: $3.42
Upside: +104.68%
Aug 7, 2024
Maintains: Outperform
Price Target: $8 → $7
Current: $3.57
Upside: +96.08%